All In Biotech

Drug Trial Radar · NCT05025241

An Open-Label Study of Oral NNZ-2591 in Phelan-McDermid Syndrome (PMS-001)

An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Phelan-McDermid Syndrome (PMS-001)

Last checked: Nov 20, 2026Latest source record: Jun 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

18

Actual

Start

Aug 8, 2022

Primary completion

Nov 1, 2023

Study completion Nov 17, 2023

Sponsor

Lead sponsor
Neuren Pharmaceuticals LimitedIndustry
Sponsor type
Industry
First posted
Aug 27, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 3 years, up to 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study of the safety, tolerability and pharmacokinetics of NNZ-2591 and measures of efficacy in children and adolescents with Phelan-McDermid Syndrome.

Conditions

  • Phelan-McDermid Syndrome

Interventions

  • NNZ-2591Drug

    NNZ-2591 oral solution (50mg/mL) to be administered twice daily dose for 13 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and TolerabilityTime frame: 13 weeks
  2. Pharmacokinetic - Mean AUC24Time frame: Pre-dose, 1-3 h post-dose and/or 4-7 h post-dose at Weeks 2, 6 and 13.
  3. Pharmacokinetic - t1/2Time frame: Pre-dose, 1-3 h post-dose and/or 4-7 h post-dose at Weeks 2, 6 and 13.

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Rush University Medical Center

    Chicago, Illinois

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Boston Children's Hospital

    Boston, Massachusetts

  • Texas Children's Hospital

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.